Studies
The Exeter IBD and Pharmacogenetics Research group is headed up by Dr Tariq Ahmad, Consultant Gastroenterologist at the Royal Devon and Exeter Hospital. It was formed in March 2011 to initially investigate the genetics around side effects caused by taking drugs used in Inflammatory Bowel Disease (IBD). The aims of the group are to raise the profile of IBD, to increase research in this field and to help to improve the health outcomes and management of patients with Crohn’s disease and ulcerative colitis. The group has built a large infrastructure across the UK and has many international collaborators in which it can conduct its research. The studies are supported by the National Institute for Health Research (NIHR) and the group receives funding and grant support from IBD charities, pharmaceutical companies and research councils.
CLARITY IBD
NIHR CRN 46188 & 55158
2020-2023
.CLARITY IBD is a UK NIHR COVID-19 urgent public health study (ISRCTN45176516) investigating the impact of biologic class and concomitant use of an immunomodulator on SARS-CoV-2 infection and immunity. This is a 64-week prospective cohort study of more than 7,000 patients with IBD treated with infliximab or vedolizumab recruited from 96 UK hospitals. The study includes data relating to SARS-CoV-2 infections and vaccinations.
PANTS
NIHR CRN 14175 & 17747 – 2014 - 2020
The PANTS study was a 3-year prospective nationwide study investigating primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab and adalimumab in patients with active luminal Crohn’s disease. 1654 patients were recruited from 118 UK hospitals. All patients were aged 6 and over, with no prior exposure to anti-TNF therapy. Clinical data and biologic specimens, including serum, DNA, and stool was collected at multiple time points and stored in the Exeter tissue bank. The biobank will store clinical, biological and genetic data from this cohort.
PRED4
NIHR CRN 86041
2012-2023
Predicting Serious Drug Side Effects in Gastroenterology (PRED4) This group of studies is looking at the following drug side effects in IBD.
- Thiopurine included myelosuppression
- Thiopurine induced pancreatitis
- Anti-TNF induced demyelination
- PPI induced interstitial nephritis
- Thiopurine Induced Liver Injury
- Sulfasalazine Induced Neutropaenia
- Thiopurine Hypersensitivity Reaction
- Immunogenicity to biologic drugs in IBD
- Anti-TNF induced adverse skin reactions in IBD
IBDGEN
NIHR CRN 9073
2008-2021
Collaborative work with the UK IBD Genetics consortium (UKIBDGC) has contributed to the discovery of more than 200 genes/loci that are associated with IBD, with Exeter IBDGEN contributing DNA from over 3000 of these study subjects. Data generated from the Exeter IBDGEN cohort have provided important and novel insights which have impacted clinical practice around the world.
© Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details and accept the service to view the translations.